To that end, the TRICE study was conducted to determine whether first-line cetuximab plus FOLFOXIRI (triplet arm) can improve the ORR compared to cetuximab plus FOLFOX (doublet arm) in RAS/BRAF wild-type CRC patients with initially technically unresectable CRLM. This evidence concerns the gene BRAF and colorectal carcinoma.